Benchmarking the Average Drug
Executive SummaryIf you had only enough money to develop one drug, which therapeutic category would you choose? Based on data of average annual sales, anti-invectives are actually bigger than cardiovascular drugs, perhaps because the entire segment is buoyed by some new, more high priced products. But the best value may be anti-virals, which deliver high annual sales on average, with a relatively short-time to market.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.